Health & Fitness
Tue, May 24, 2011Mon, May 23, 2011Sun, May 22, 2011Fri, May 20, 2011Thu, May 19, 2011Wed, May 18, 2011Tue, May 17, 2011Mon, May 16, 2011Sun, May 15, 2011Fri, May 13, 2011Thu, May 12, 2011Wed, May 11, 2011Tue, May 10, 2011Mon, May 9, 2011Sun, May 8, 2011Sat, May 7, 2011Fri, May 6, 2011Thu, May 5, 2011Wed, May 4, 2011Tue, May 3, 2011Mon, May 2, 2011Fri, April 29, 2011Thu, April 28, 2011Wed, April 27, 2011Tue, April 26, 2011Mon, April 25, 2011Orthovita to Present at the Bank of America Merrill Lynch Health Care Conference
Published in Health and Fitness on Tuesday, May 10th 2011 at 13:10 GMT by Market Wire
MALVERN, Pa.--([ BUSINESS WIRE ])--Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today that it will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas. Antony Koblish, President and Chief Executive Officer of Orthovita, is scheduled to present on Thursday, May12, 2011, at 9:50a.m. Pacific Time, at the Encore at Wynn Las Vegas, 3121 Las Vegas Boulevard South, Las Vegas, NV 89109. A live audio webcast of the presentation will be available, and can be accessed through Friday, May 27, 2011, by visiting [ http://www.veracast.com/webcasts/baml/healthcare2011/id45234200.cfm ].
About the Company
Orthovita, Inc. is a specialty spine and orthopedic company with a portfolio of orthobiologic and biosurgery products. Our products are based on novel and unique proprietary biomaterials that have innovative mechanisms of action in the body. Our orthobiologic platform offers products for the fusion, regeneration and fixation of human bone. Our biosurgery platform offers products for controlling intra-operative bleeding, also known as hemostasis. Our current fusion and regeneration products are based on our proprietary VitossTM Bone Graft Substitute technology and address the non-structural bone graft market with synthetic, bioactive alternatives to patient- and cadaver-derived bone tissue. CortossTM Bone Augmentation Material, an injectable, polymer composite that mimics the mechanical properties of weight-bearing human cortical bone, provides the basis for our fixation portfolio. Our hemostasis portfolio includes VitagelTM Surgical Hemostat, a proprietary, collagen-based matrix that controls bleeding and facilitates healing, and Vitasurea" Absorbable Hemostat, a plant-based product that can be deployed quickly throughout surgery.
Disclosure Notice
This press release may contain forward-looking statements regarding Orthovitaa™s current expectations of future events that involve risks and uncertainties, including, without limitation, the demand and market acceptance of our products and other aspects of our business.Such statements are based on managementa™s current expectations and are subject to a number of substantial risks and uncertainties that could cause actual results or timeliness to differ materially from those addressed in the forward-looking statements.Factors that may cause such a difference are listed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission (SEC), including but not limited to risks described in our most recently filed Form 10-K under the caption aRisk Factors.aFurther information about these and other relevant risks and uncertainties may be found in Orthovitaa™s filings with the SEC, all of which are available from the SEC as well as other sources.Orthovita undertakes no obligation to publicly update any forward-looking statements.
